PRSS37 Activators
PRSS37 Activators encompass a variety of chemical compounds that influence different signaling pathways, ultimately leading to the enhanced activity of the serine protease PRSS37. Forskolin and Dibutyryl cyclic AMP act as cAMP elevators, which lead to the activation of protein kinase A (PKA), a central kinase that can phosphorylate several substrates, potentially including those that regulate PRSS37. Similarly, 3-Isobutyl-1-methylxanthine (IBMX) prevents the breakdown of cAMP, thereby sustaining the activation ofPKA and enhancing the functional activity of PRSS37 through prolonged signaling. The increase in PKA activity could result in phosphorylation events that indirectly enhance PRSS37 activity by altering the regulatory protein-protein interactions or modifying the protease itself. Sildenafil and Zaprinast, by inhibiting phosphodiesterase type 5, prevent the breakdown of cGMP and indirectly promote signaling pathways that may involve protein kinase G (PKG), potentially augmenting PRSS37 activity. L-Arginine contributes to this process by being a precursor for nitric oxide synthesis, which stimulates guanylate cyclase to produce cGMP, further influencing PRSS37 through PKG activation.
In addition to cAMP and cGMP pathways, other signaling molecules and pathways play a role in modulating PRSS37 activity. The polyphenol Epigallocatechin gallate (EGCG) inhibits certain kinases, potentially reducing competitive signaling and indirectly upregulating pathways that activate PRSS37. Y-27632's inhibition of Rho-associated protein kinase (ROCK) leads to changes in cytoskeletal dynamics, which could indirectly enhance the proteolytic activity of PRSS37 by altering substrate availability or localization. Phorbol 12-myristate 13-acetate (PMA) activates protein kinase C (PKC), and the subsequent downstream phosphorylation events might increase PRSS37 activity through altered cellular signaling. Anisomycin, through its ability to activate stress-activated protein kinases such as JNK, may influence cellular signaling pathways that result in the enhancement of PRSS37 activity through stress response mechanisms. Lastly, LY294002 inhibits PI3K, potentially leading to the activation of alternative signaling pathways that may upregulate the function of PRSS37, demonstrating the intricate web of cellular signaling that governs the activity of this protease.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin is a labdane diterpene that activates adenylate cyclase, leading to increased cAMP levels in cells. The rise in cAMP can enhance PRSS37 activity by promoting signaling pathways that involve protein kinase A (PKA), which may phosphorylate proteins that regulate the protease function of PRSS37. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
This compound is a non-selective inhibitor of phosphodiesterases, resulting in increased cAMP levels by preventing its breakdown. The subsequent activation of PKA could lead to phosphorylation events that indirectly enhance PRSS37 activity. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $47.00 $136.00 $492.00 $4552.00 | 74 | |
This compound is a cell-permeable analog of cAMP that can activate PKA. By mimicking cAMP, it can bypass the need for adenylate cyclase activity, directly stimulating pathways that involve PKA, potentially leading to the phosphorylation of regulatory proteins and the enhanced activity of PRSS37. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG is a polyphenol found in green tea with various biological effects including kinase inhibition. By inhibiting certain kinases, it may decrease competitive signaling and indirectly upregulate signaling pathways that result in the activation of PRSS37. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Zaprinast is another phosphodiesterase inhibitor that increases cGMP levels, potentially activating PKG and influencing pathways that could enhance the activity of PRSS37. | ||||||
L-Arginine | 74-79-3 | sc-391657B sc-391657 sc-391657A sc-391657C sc-391657D | 5 g 25 g 100 g 500 g 1 kg | $20.00 $31.00 $61.00 $219.00 $352.00 | 2 | |
L-Arginine is a substrate for nitric oxide synthase, leading to the production of nitric oxide (NO). NO can stimulate guanylate cyclase to produce cGMP, thus activating PKG, which may then activate signaling pathways that enhance PRSS37 activity. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a selective inhibitor of Rho-associated protein kinase (ROCK), which can modulate cytoskeletal dynamics. By inhibiting ROCK, Y-27632 may alter cellular processes in a way that indirectly enhances the proteolytic activity of PRSS37. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
Phorbol 12-myristate 13-acetate (PMA) is a potent activator of protein kinase C (PKC). PKC activation can lead to downstream phosphorylation events that might increase the functional activity of PRSS37 through altered cellular signaling. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $99.00 $259.00 | 36 | |
Anisomycin is a protein synthesis inhibitor that can activate stress-activated protein kinases like JNK. This activation may influence cellular signaling pathways that indirectly result in the enhancement of PRSS37 activity through stress response mechanisms. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor, which might enhance PRSS37 activity by affecting pathways downstream of PI3K, such as the AKT signaling cascade. Inhibiting AKT can have diverse effects on cellular processes, potentially leading to the activation of alternative pathways that may upregulate the function of PRSS37. | ||||||